ClinicalTrials.gg
Status unknownNCT04801017Updated Mar 16, 2021

A Study to Evaluate the Safety and Efficacy of OT-101+Artemisinin in Hospitalized COVID-19 Subjects

A Phase 2 interventional study of OT-101 and Artemisinin in COVID-19, sponsored by Oncotelic Inc.. Status unknown at 1 site in Brazil. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-03-16.

Sponsored by Oncotelic Inc. · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Feb 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 317 studies in COVID-19 with a site in Brazil — 20 open to participants now, 28 under way, 9 of them phase 3. COVID-19 · Brazil.

Planned enrollment
244th of 263
18 · median 205
Started
2021
with 102 others
Phase 2
56 of 317
2 open now
Registered
184th of 317
by date

Among the 317 studies in COVID-19 with a site in Brazil, this one is the 244th largest by planned enrollment of the 263 interventional ones that give a count, is one of 103 that started in 2021, is one of 56 in phase 2, and was the 184th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

20 of the 317 studies in COVID-19 with a site in Brazil are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 317 studies in COVID-19 with a site in Brazil, or all of them as a file.
02

Study summary

Primary Objective is to evaluate the safety and efficacy of OT-101+Artemisinin when used in combination with standard of care (SoC) in hospitalized COVID 19 subjects versus SoC+ Artemisinin+Placebo.

Read the detailed description

This is a randomized, double blind, placebo controlled study to evaluate the efficacy, safety and tolerability of OT-101+Artemisinin when used in combination with SoC in hospitalized subjects with severe COVID 19. Written informed consent must be obtained from all subjects or their legally authorized representative (LAR) during screening (up to Day 3 prior to dosing) and prior to study related procedures being performed. Following completion of all screening assessments and meeting of eligibility criteria, subjects will be enrolled and randomized on Day 1 to either receive OT-101+Artemisinin or placebo+Artemisinin in a 2:1 ratio for 7 days in combination with SoC therapy per local SoC policies, followed to Day 28.

Subjects: includes subjects with severe COVID 19 (WHO COVID 19 Clinical Improvement Ordinal Scale 5 - non-invasive ventilation or high flow oxygen, or 6 - intubation and mechanical ventilation) at screening.

Subjects will undergo assessment during hospitalization or could discontinue their treatment with OT 101 or placebo during the 7 day infusion period or any time later during the study. All subjects will be closely monitored for adverse events (AEs) from signing the informed consent form (ICF) for at least 21 days after the final dose of study treatment (until Day 28). Standard of care treatment may continue as clinically indicated (after the 7 day dosing completion) as per local institutional guidelines. If subjects are discharged after Day 7 (after completing dosing), post discharge assessments can be done either at home (home health visit) or at the site. For subjects who are discharged before Day 28 or who withdraw from the study early will have follow up phone calls or will be followed up at site or a home visit to collect safety data until End of Study on Day 28. On days of laboratory assessments, discharged subjects may have a home visit.

03

Conditions studied

  • COVID-19

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Hospitalized adult male or non-pregnant, non-lactating female subjects (between 18 and 80 years), with SARS-CoV-2 (previously known as 2019-nCoV) infection that is documented by authorized diagnostic PCR test. A rapid PCR test could also be used. Confirmation that subject has COVID-19 within the last 2 weeks prior to randomization.
  2. Meeting WHO COVID 19 Clinical Improvement Ordinal Scale Criteria 5 (non-invasive mechanical ventilation or high-flow oxygen) or Criteria 6 (intubation and mechanical ventilation).
  3. O2 sat \<= 93%
  4. Male subjects and female subjects of must agree to use protocol specified methods of .
  5. Female subjects of childbearing potential and women of non childbearing potential (defined as at least 2 years or permanently sterilized women [bilateral tubal ligation, bilateral ovariectomy, or hysterectomy]) must have a negative serum pregnancy test at screening or pretreatment on Day 1.
  6. The subject or a LAR has provided written .
  7. The subject or the LAR is aware of the nature of this study and willing to comply with protocol treatments, and other evaluations listed in the ICF.

Exclusion criteria

Exclusion Criteria:

  1. Participation in any other clinical trial of an experimental treatment for COVID-19 or participation in another interventional clinical trial, including an expanded access trial.
  2. Concurrent treatment with other agents with actual or possible direct acting antiviral activity against SARS CoV 2 infection \<24 hours prior to study drug dosing except for remdesivir.
  3. Uncontrolled hypertension (systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg), unstable angina, congestive heart failure of any New York Respiratory Association classification, serious cardiac arrhythmia requiring treatment (exceptions: atrial fibrillation, paroxysmal supraventricular tachycardia), or history of myocardial infarction within 12 months of enrollment.
  4. Hypotension requiring vasoactive peptides, such as dopamine, norepinephrine, epinephrine, or dobutamine.
  5. Renal function impairment ( [Cr. Cl.] \<50 mL/min, based on Modification of Diet in Renal Disease calculation).
  6. Liver function impairment

    1. (ALT) or aspartate aminotransferase (AST) >5 × (ULN), or ALT/AST >3 × ULN plus total >2 × ULN.
    2. Total bilirubin >1.5 × ULN, unless the subject has known Gilbert's syndrome.
  7. count \<50 000/µL
  8. Multi-organ failure.
  9. Document active infection with a bacterial pathogen requiring parenteral systemic antibiotics.
  10. Bacterial or fungal sepsis.
  11. History of within the last 4 weeks prior to study enrollment; subjects must not receive live, attenuated influenza vaccine (eg, FluMist) within 4 weeks before enrolment or at any time during the study.
  12. History of an allergic reaction or to the study drug or any component of the study drug formulation.
  13. Anti-inflammatory treatments other than (eg, complement inhibitor, anti-GM-CSF antibody, anti-IL6 antibody) ARE PROHIBITED. However, antiviral drugs (eg, remdesivir,), systemic corticosteroids, and non steroidal anti inflammatory drugs (NSAIDs) ARE ALLOWED.
  14. Presence of any uncontrolled concomitant illness, serious illness, medical conditions, or other medical history, including laboratory results, which, in the Investigator's opinion, would be likely to interfere with their participation in the study.
  15. Major surgical procedure within 4 weeks prior to screening or anticipation of need for major surgical procedure during the course of the study.
  16. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to screening
  17. History of organ allograft.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    OT-101 + Artemisinin + Standard of Care

    OT-101 - Days 1 to 7: 140 mg/m2 daily intravenous (i.v.) infusion for 7 continuous days. Artemisinin: Days 1 to 5: 500 mg per day for 5 days by oral

    Drug: OT-101 · Drug: Artemisinin

  • Placebo comparator
    Placebo + Artemisinin + Standard of Care

    Artemisinin: Days 1 to 5: 500 mg per day for 5 days by oral

    Drug: Artemisinin · Drug: Placebo

Interventions

  • DrugTrabedersenStudies of TrabedersenTrabedersen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    TGF β2 specific synthetic 18 mer phosphorothioate antisense oligodeoxynucleotide

    Also known as: Trabedersen

  • Herbal Supplement/ Purified extract from Artemisia

    Also known as: ArtiVeda

  • DrugPlacebo

    0.9% sodium chloride injection

    Also known as: Normal saline

06

What researchers measure

Primary outcomes

  1. The proportion of subjects with clinical improvement score measured by an 8-point WHO COVID-19 Clinical Improvement Ordinal Scale as assessed by the odds ratio (OR) at Day 14.

    Clinical improvement is defined as • A score decrease to categories 1, 2, 3, or 4.

    Time frame: at Day 14

Secondary outcomes

  1. The OR at Days 7, 21, and 28 based on the clinical improvement score (as measured by an 8 point WHO COVID 19 Clinical Improvement Ordinal Scale).

    Clinical improvement defined as per primary endpoint.

    Time frame: at Day 7, 21, 28

  2. The OR at Days 7, 14, 21, and 28 of a decrease of at least 1, 2, 3, and 4 points in subjects with severe COVID 19.

    Time frame: at Day 7, 14, 21, 28

  3. Time to at least 2 point improvement from baseline on Days 7, 14, 21, and 28 in subjects with severe COVID 19.

    Time frame: at Day 7, 14, 21, 28

  4. Worsening (increase in clinical improvement score) of at least '1' score on Days 7, 14, 21, and 28.

    Time frame: at Day 7, 14, 21, 28

  5. Mortality by Days 7, 14, 21, and 28.

    Time frame: up to Day 28

  6. Duration of supplemental oxygen/ventilator support by Days 7, 14, 21, and 28.

    Time frame: up to Day 28

  7. Duration of intensive care unit stay by Days 7, 14, 21, and 28.

    Time frame: up to Day 28

  8. Duration of hospitalization by Days 7, 14, 21, and 28.

    Time frame: up to Day 28

  9. Ventilator free days by Day 14 and Day 28.

    Time frame: up to Day 28

  10. Days on ventilation.

    Time frame: up to Day 28

Other outcomes

  1. Incidence of AEs and treatment-emergent AEs (TEAEs).

    Time frame: up to 28 days

  2. Adverse events leading to premature discontinuation of the study treatment.

    Time frame: up to 28 days

  3. Changes in radiology tests (chest X-ray or chest computed tomography [CT]) from baseline.

    Time frame: up to 28 days

07

Study locations

1 site
  • Praxis Pesquisa Medica S / S Ltda
    Jardim, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2021; primary completion for Aug 2021, 4 months later.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's planned 4 months is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2021
First posted
Mar 16, 2021
StartEst.
Apr 2021
Primary completionEst.
Aug 2021
CompletionEst.
Oct 2021
Last update
Mar 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04801017
Lead sponsor
Oncotelic Inc.
Responsible party
Sponsor
First posted
Mar 16, 2021
Start date
Apr 2021 (estimated)
Primary completion
Aug 2021 (estimated)
Completion
Oct 2021 (estimated)
Last update
Mar 16, 2021

Study contacts

Federico Lerner, MD
Contact
federico@latinaba.com
54 (911) 2852.0457
Vuong Trieu, PhD
study director · Oncotelic Inc.

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trabedersen

Start the discussion